Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).

Patients will receive maraviroc 300 mg twice daily for 14 days

Subjects randomized to control group will be on standard care treatment according to the Ministry of Health and Local Guidelines and Protocols.